Immatics N.V.
IMTX Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 27, 2026
$7.26
KIRA · Stoqly’s AI analyst, in plain words
- Immatics N.V. lost $222M in fiscal 2025.
- Free cash flow was −$207M in fiscal 2025, — of revenue.
Market cap
$888M
P/E
—
Revenue
—
Net income
−$222M
Free cash flow
−$207M
Operating margin
—
Immatics N.V. in 30 seconds · fiscal 2025
Does it make a profit?
−$222M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Immatics N.V. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 5, 2026
- Legal name
- Immatics N.V.
- CIK
- 0001809196
Immatics N.V. · IMTX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$110M | $29.1M | −$102M | $16.5M | −$222M |
| Diluted EPS | −$1.75 | $0.42 | −$1.28 | $0.15 | −$1.82 |
| Cash | |||||
| Cash from operations | −$100M | $105M | $19.7M | −$171M | −$199M |
| Capital expenditure | $6.0M | $6.0M | $33.3M | $17.6M | $7.4M |
| Free cash flow | −$106M | $99.2M | −$13.6M | −$189M | −$207M |
| Share count change | 31.1% | 9.4% | 17.0% | 32.6% | 14.6% |
| Debt and strength | |||||
| Cash and short-term investments | $151M | $158M | $241M | $246M | $406M |
| Shareholders' equity | $27.3M | $217M | $240M | $597M | $569M |
| Current ratio | 1.6x | 3.5x | 2.9x | 9.3x | 11.7x |
| Interest coverage | −152.5x | 28.9x | −122.4x | −43.6x | −192.4x |
| Returns and quality | |||||
| Return on equity | −164.2% | 23.9% | −44.8% | 3.9% | −38.0% |
| Return on tangible equity | −428.4% | 13.5% | −42.9% | 2.8% | −39.1% |
| Altman Z'' | −11.2 | 1.8 | −0.6 | 7.1 | 5.2 |
Insiders bought, 12 months
$7.5M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Immatics N.V. · IMTX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $7.26 a share, the company is worth $888M.
Source: SEC EDGAR XBRL filings (CIK 0001809196). Data updated October 24, 2026. Filed in EUR under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.